...
首页> 外文期刊>Journal of reconstructive microsurgery >Microsurgical techniques for the treatment of breast cancer - Related lymphedema: A systematic review
【24h】

Microsurgical techniques for the treatment of breast cancer - Related lymphedema: A systematic review

机译:显微外科技术治疗乳腺癌-相关淋巴水肿:系统评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Upper limb lymphedema is one of the most underestimated and debilitating complications of breast cancer treatment. The aim of this review is to summarize the recent literature for evidence of the effectiveness of lymphatic microsurgery for the treatment of breast cancer-related lymphedema (BCRL). Methods A search was conducted for articles published from January 2000 until January 2012. Only studies on secondary lymphedema after breast cancer treatment and those examining the effectiveness of microsurgery were included. Results No randomized clinical trials or comparative studies were available. Ten case-series met inclusion criteria: (composite) tissue transfer (n = 4), lymphatic vessel transfer (n = 2), and derivative microlymphatic surgery (n = 4). Limb volume/circumference reduction varied from 2 to 50% over a follow-up time ranging from 1 to 132 months. Postoperative discontinuation rates of conservative therapy were only reported after composite tissue transfer, ranging from 33 to 100% after 3 to 24 months. Clear selection criteria for lymphatic surgery and lymphatic flow assessment were absent in most studies. Conclusion We identified important methodological shortcomings of the available literature. Evidence acquired through comparative studies with uniform patient selection is lacking. Consistent positive findings with regards to limb volume reduction and limited complications are reasons to further explore these techniques in methodologically superior studies.
机译:背景技术上肢淋巴水肿是乳腺癌治疗中被低估和使人衰弱的并发症之一。这篇综述的目的是总结最近的文献,作​​为淋巴显微手术治疗乳腺癌相关淋巴水肿(BCRL)的证据。方法对2000年1月至2012年1月发表的文章进行检索。仅包括乳腺癌治疗后继发性淋巴水肿的研究以及显微手术的有效性研究。结果尚无随机临床试验或比较研究。十个病例系列符合纳入标准:(复合)组织转移(n = 4),淋巴管转移(n = 2)和衍生性微淋巴手术(n = 4)。在1到132个月的随访时间内,肢体体积/周围环境的减少从2%到50%不等。仅在复合组织转移后才报道保守治疗的术后停药率,在3至24个月后为33%至100%。在大多数研究中,没有明确的淋巴手术选择标准和淋巴流量评估标准。结论我们确定了现有文献的重要方法学缺陷。缺乏通过比较研究获得统一患者选择的证据。关于减少肢体体积和有限并发症的一致阳性结果是在方法学上更高级的研究中进一步探索这些技术的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号